Chromogranin A assay in clinical practice.

[1]  J. Conlon,et al.  Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors , 2010, Regulatory Peptides.

[2]  N. Mahapatra,et al.  Chromogranin A: a novel susceptibility gene for essential hypertension , 2010, Cellular and Molecular Life Sciences.

[3]  D. O'Connor,et al.  Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification. , 2010, Physiological genomics.

[4]  D. O'Connor,et al.  Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse. , 2009, Endocrinology.

[5]  B. King,et al.  Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. , 2009, Endocrine-related cancer.

[6]  K. A. Al-Shoumer,et al.  Serum chromogranin A concentration in hyperthyroidism before and after medical treatment. , 2009, The Journal of clinical endocrinology and metabolism.

[7]  M. Bardella,et al.  Plasma chromogranin a in patients with inflammatory bowel disease , 2009, Inflammatory bowel diseases.

[8]  N. Patronas,et al.  Diagnostic accuracy of chromogranin A and calcitonin precursors measurements for the discrimination of ectopic ACTH secretion from Cushing's disease. , 2009, The Journal of clinical endocrinology and metabolism.

[9]  A. Sciarra,et al.  Distribution of High Chromogranin A Serum Levels in Patients with Nonmetastatic and Metastatic Prostate Adenocarcinoma , 2009, Urologia Internationalis.

[10]  B. Skogseid,et al.  Elevated Plasma Chromogranin A Is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumors , 2009, Neuroendocrinology.

[11]  M. Vatn,et al.  Small intestinal neuroendocrine tumors: Prognostic factors and survival , 2009, Scandinavian journal of gastroenterology.

[12]  M. Merino,et al.  Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. , 2008, The Journal of clinical endocrinology and metabolism.

[13]  B. Skogseid,et al.  Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution , 2008, Clinical Cancer Research.

[14]  T. Omland,et al.  Prognostic value of circulating chromogranin A levels in acute coronary syndromes , 2008, European heart journal.

[15]  J. Ardill.  Circulating markers for endocrine tumours of the gastroenteropancreatic tract , 2008, Annals of clinical biochemistry.

[16]  D. Aunis,et al.  Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. , 2008, Clinical chemistry.

[17]  D. O'Connor,et al.  Heritability and Genome-Wide Linkage in US and Australian Twins Identify Novel Genomic Regions Controlling Chromogranin A: Implications for Secretion and Blood Pressure , 2008, Circulation.

[18]  K. Klose,et al.  Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  Douglas W. Smith,et al.  Chromogranin A polymorphisms are associated with hypertensive renal disease. , 2008, Journal of the American Society of Nephrology : JASN.

[20]  E. Baudin,et al.  Tumeurs neuro-endocrines , 2008 .

[21]  D. O'Connor,et al.  Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin. , 2008, Endocrinology.

[22]  P. Munson,et al.  Chromogranin a expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[23]  P. Igaz,et al.  Marked chromogranin A elevation in a patient with bilateral adrenal incidentalomas, and its rapid normalization after discontinuation of proton pump inhibitor therapy , 2007, Clinical endocrinology.

[24]  F. D. De Braud,et al.  Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. , 2007, Endocrine-related cancer.

[25]  R. Pezzilli,et al.  Chromogranin A: is it a useful marker of neuroendocrine tumors? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  F. Pattou,et al.  An analysis of the biochemical diagnosis of 66 pheochromocytomas. , 2007, European journal of endocrinology.

[27]  L. Ceriani,et al.  False-positive serum chromogranin A assay due to heterophile antibody interference. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[28]  J. Rehfeld,et al.  Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas. , 2007, Clinical chemistry.

[29]  E. Baudin.  Gastroenteropancreatic endocrine tumors: clinical characterization before therapy , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[30]  W. Herder.  Biochemistry of neuroendocrine tumours , 2007 .

[31]  A. Tischler,et al.  Pheochromocytoma: recommendations for clinical practice from the First International Symposium , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[32]  M. Boniardi,et al.  The role of chromogranin A in the management of patients with phaeochromocytoma , 2006, Clinical endocrinology.

[33]  D. O'Connor,et al.  The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters , 2006, Journal of hypertension.

[34]  A. Lazaris,et al.  Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. , 2005, Urology.

[35]  F. D. De Braud,et al.  Comparison between Two Methods in the Determination of Circulating Chromogranin A in Neuroendocrine Tumors (NETs): Results of a Prospective Multicenter Observational Study , 2005 .

[36]  D. Conte,et al.  Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. , 2005, European journal of endocrinology.

[37]  G. Sassolas,et al.  Interest of Chromogranin A for diagnosis and follow‐up of endocrine tumours , 2004, Clinical endocrinology.

[38]  P. Chanson,et al.  Chromogranin A as serum marker of pituitary adenomas , 2003, Clinical endocrinology.

[39]  E. Bravo,et al.  Pheochromocytoma: state-of-the-art and future prospects. , 2003, Endocrine reviews.

[40]  R. Jensen,et al.  Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas , 2003, Cancer.

[41]  M. Walther,et al.  Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. , 2003, The Journal of clinical endocrinology and metabolism.

[42]  M. Stridsberg,et al.  A comparison between three commercial kits for chromogranin A measurements. , 2003, The Journal of endocrinology.

[43]  D. O'Connor,et al.  The chromogranin-secretogranin family. , 2003, The New England journal of medicine.

[44]  W. Young,et al.  A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. , 2003, The Journal of clinical endocrinology and metabolism.

[45]  M. Walther,et al.  Biochemical diagnosis of pheochromocytoma: which test is best? , 2002, JAMA.

[46]  D. Huglo,et al.  Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  E. Baudin,et al.  Chromogranin A and the α -subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma , 2001, British Journal of Cancer.

[48]  M. Ferdeghini,et al.  RELATIONSHIP BETWEEN RENAL FUNCTION AND BLOOD LEVEL OF CHROMOGRANIN A , 2001, Renal failure.

[49]  E. Seregni,et al.  Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors , 1999, Cancer.

[50]  B. Skogseid,et al.  Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. , 1999, The Journal of clinical endocrinology and metabolism.

[51]  D. Venzon,et al.  Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas , 1999, Cancer.

[52]  D. Pons-Anicet,et al.  A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245) , 1999, British Journal of Cancer.

[53]  L. Mariani,et al.  5‐fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors , 1998, Cancer.

[54]  L. Deftos,et al.  Granins and prostate cancer. , 1998, Urology.

[55]  D. O'Connor,et al.  Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. , 1997, The Journal of clinical investigation.

[56]  E. Krenning,et al.  Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. , 1997, The Journal of clinical endocrinology and metabolism.

[57]  L. Holmberg,et al.  Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  M. Stridsberg,et al.  Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma. , 1996, The Journal of endocrinology.

[59]  A. Funakoshi,et al.  Comparison of chromogranin A and pancreastatin levels in plasma of patients with pancreatic islet cell tumor. , 1995, Life sciences.

[60]  R. Bouillon,et al.  Serum chromogranin A in the differential diagnosis of Cushing's syndrome. , 1994, European journal of endocrinology.

[61]  R. Angeletti,et al.  Chromogranin A: a multipurpose prohormone? , 1994, Acta physiologica Scandinavica.

[62]  M. P. Canale,et al.  Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. , 1994, The Journal of clinical endocrinology and metabolism.

[63]  D. Aunis,et al.  Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. , 1993, European journal of biochemistry.

[64]  G. Greeley,et al.  Parastatin (porcine chromogranin A347-419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion. , 1993, Endocrinology.

[65]  D. O'Connor,et al.  Immunoluminometric assay of chromogranin A in serum with commercially available reagents. , 1992, Clinical chemistry.

[66]  D. O'Connor,et al.  Structure and function of the chromogranin A gene. Clues to evolution and tissue-specific expression. , 1991, The Journal of biological chemistry.

[67]  D. O'Connor,et al.  Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimulation of endocrine glands. , 1990, The Journal of clinical endocrinology and metabolism.

[68]  D. O'Connor,et al.  Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. , 1990, The Journal of clinical investigation.

[69]  D. O'Connor,et al.  Chromogranin A in uremia: progressive retention of immunoreactive fragments. , 1990, Kidney international.

[70]  A. Vinik,et al.  Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors. , 1989, The Journal of clinical endocrinology and metabolism.

[71]  D. O'Connor,et al.  Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. , 1989, Clinical chemistry.

[72]  D. O'Connor,et al.  Human pituitary tumors secrete chromogranin-A. , 1989, The Journal of clinical endocrinology and metabolism.

[73]  D. O'Connor,et al.  Secretion of chromogranin A by peptide-producing endocrine neoplasms. , 1986, The New England journal of medicine.

[74]  D. O'Connor,et al.  Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. , 1984, The New England journal of medicine.

[75]  A. D. Smith,et al.  Secretion of a Chromaffin Granule Protein, Chromogranin, from the Adrenal Gland after Splanchnic Stimulation , 1967, Nature.

[76]  K. Helle,et al.  The release of protein from the stimulated adrenal medulla. , 1965, The Biochemical journal.

[77]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.

[78]  M. Schott.  Serum Chromogranin A Concentration in Hyperthyroidism before and after Medical Treatment , 2010 .

[79]  W. Young,et al.  Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. , 2008, The Journal of clinical endocrinology and metabolism.

[80]  A. Paradiso,et al.  An Italian program of External Quality Control for chromogranin A (CgA) assay: performance evaluation of CgA determination , 2007, Clinical chemistry and laboratory medicine.

[81]  W. D. de Herder.  Biochemistry of neuroendocrine tumours. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[82]  E. Bravo,et al.  Pheochromocytoma : State-ofthe-Art and Future Prospects , 2003 .

[83]  D. Aunis,et al.  Chromogranines : de la découverte à la fonction. , 2001 .

[84]  E. Baudin,et al.  Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[85]  E. Seregni,et al.  Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  R. Mayer,et al.  Carcinoid tumors. , 1999, The New England journal of medicine.

[87]  R. Mayer,et al.  Medical progress : Carcinoid tumors , 1999 .

[88]  T. Shimazoe,et al.  Pancreastatin molecular forms in normal human plasma. , 1994, Life sciences.

[89]  D. O'Connor,et al.  Chromogranin A as tumor marker in medullary thyroid carcinoma. , 1992, Thyroid : official journal of the American Thyroid Association.